Ascendis Pharma has received FDA approval for its hypoparathyroidism therapy, Yorvipath, providing an alternative to the Takeda Pharmaceutical drug Natpara that is set to be discontinued. Yorvipath aims to bring parathyroid hormone levels within the normal range, addressing the deficiency that causes issues with calcium and phosphate regulation in the body. The drug, a once-daily injection, has shown positive results in clinical trials, offering hope for the 70,000 to 90,000 patients in the U.S. affected by the rare disease. Ascendis plans to launch Yorvipath in the U.S. in early 2025 after gaining European approval and is working on pricing and commercial availability.
Source link
Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency
